# Bemarituzumab in FGFR2b+ Patients With Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction, Who Failed at Least One Prior Line of Palliative Chemotherapy

> **NCT06680622** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest** · enrollment: 126 (estimated)

## Conditions studied

- Metastatic Gastro-esophageal Adenocarcinoma

## Interventions

- **DRUG:** bemarituzumab, paclitaxel, ramucirumab
- **DRUG:** bemarituzumab, irinotecan
- **DRUG:** bemarituzumab, trifluridine/tipiracil

## Key facts

- **NCT ID:** NCT06680622
- **Lead sponsor:** Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-03-03
- **Primary completion:** 2027-09
- **Final completion:** 2028-03
- **Target enrollment:** 126 (ESTIMATED)
- **Last updated:** 2026-01-07

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06680622

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06680622, "Bemarituzumab in FGFR2b+ Patients With Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction, Who Failed at Least One Prior Line of Palliative Chemotherapy". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT06680622. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*